Agent for preventing or treating mild cognitive impairment
WO2020262555A1
Side effect reducing agent for nucleic acid drug, medicinal composition comprising side effect reducing agent for nucleic acid drug, and method for reducing side effect inducing properties of nucleic acid drug
WO2020246535A1
Htlv-i-specific ctl activator
WO2020241681A1
Antibacterial composition
WO2020209285A1
Pharmaceutical composition for muscle disease treatment
WO2020196801A1
Skin composition
WO2020196662A1
Double-stranded nucleic acid complex and use thereof
WO2020196233A1
Composition for promoting cartilage tissue regeneration
WO2020179931A1
High-throughput gene-editing technique
WO2020175502A1
Fusion protein of antigen-binding protein and fluorescent protein or fluorescence-labeled tag protein
WO2020175366A1
Chimeric antigen receptor
WO2020171149A1
Optimal ps modification pattern for heteronucleic acids
WO2020158811A1
Method for identifying helicobacter pylori strain and kit for identification
WO2020158260A1
Method and system for examining atrial arrhythmias
WO2020188938A1
Tachyarrhythmia examination method and tachyarrhythmia examination system
WO2020183857A1
Atrial fibrillation analytical apparatus, atrial fibrillation analytical method, and program
WO2020100779A1
Monoclonal antibody specifically binding to pser46-marcks
WO2020090683A1
Method for obtaining information on risk of reduced respiratory function in patient with interstitial pneumonia, and use thereof
